BioCentury
ARTICLE | Clinical News

AGN-150998: Phase II data

May 6, 2013 7:00 AM UTC

Allergan disclosed on its 1Q13 earnings call that an initial analysis of the second stage of a double-blind, international Phase II trial comparing 2 intravitreal injections of AGN-150998 to Lucentis...